Anti-IRF3 antibody
4
(3 Reviews)
|
(42 Publications)
Rabbit Polyclonal IRF3 antibody. Suitable for WB and reacts with Human samples. Cited in 42 publications. Immunogen corresponding to Synthetic Peptide within Human IRF3.
View Alternative Names
Interferon regulatory factor 3, IRF-3, IRF3
- WB
Unknown
Western blot - Anti-IRF3 antibody (AB25950)
Lane 1:
Western blot - Anti-IRF3 antibody (ab25950) at 1 µg/mL
Lane 2:
Western blot - Anti-IRF3 antibody (ab25950) at 2 µg/mL
Lane 3:
Western blot - Anti-IRF3 antibody (ab25950) at 4 µg/mL
All lanes:
Ramos whole cell lysate.
Predicted band size: 47 kDa
Observed band size: ~44 kDa
false
- WB
AbReview58058****
Western blot - Anti-IRF3 antibody (AB25950)
Samples were incubated with primary antibody for 18 hours at 4°C and blocked with 5% BSA for 1 hour at room temperature.
All lanes:
Western blot - Anti-IRF3 antibody (ab25950) at 1/1000 dilution
All lanes:
HT-29 at 30 µg
Secondary
All lanes:
HRP conjugated Anti-rabbit IgG, Goat polyclonal at 1/1000 dilution
Predicted band size: 47 kDa
true
This image is courtesy of an anonymous Abreview
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF3 participates in the regulation of type I interferon (IFN) response a fundamental antiviral defense mechanism. IRF3 when phosphorylated forms a complex with CBP/p300 which then translocates to the nucleus to drive the expression of IFN-stimulated genes. This action strengthens the innate immune response and boosts the body's ability to counteract viral infections. Its activity and regulation are significant for maintaining a balanced immune response without excessive inflammation.
Pathways
IRF3 is involved in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) signaling pathways both essential in pathogen recognition and response. Within these pathways IRF3 interacts with proteins such as MAVS and TBK1 to propagate immune signaling. The activation of IRF3 in these pathways results in the production of type I interferons and other cytokines orchestrating an effective antiviral response. These interactions highlight the protein's central role in mediating immune signaling cascades.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (42)
Recent publications for all applications. Explore the full list and refine your search
PLoS pathogens 21:e1013443 PubMed40875754
2025
Applications
Unspecified application
Species
Unspecified reactive species
Bioactive materials 24:37-53 PubMed36582350
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in immunology 13:1020262 PubMed36248821
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 13:640 PubMed35869062
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of virology 96:e0102222 PubMed35861515
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell cycle (Georgetown, Tex.) 21:767-779 PubMed35130108
2022
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 17:e1010142 PubMed34929018
2021
Applications
Unspecified application
Species
Unspecified reactive species
Journal of virology 95: PubMed33536170
2021
Applications
Unspecified application
Species
Unspecified reactive species
Open medicine (Warsaw, Poland) 16:581-590 PubMed33869780
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in veterinary science 7:570593 PubMed33240950
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com